...
首页> 外文期刊>Nature Communications >Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
【24h】

Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors

机译:对原发性肿瘤纯合缺失的全癌分析发现了罕见的肿瘤抑制因子

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Homozygous deletions are rare in cancers and often target tumour suppressor genes. Here, we build a compendium of 2218 primary tumours across 12 human cancer types and systematically screen for homozygous deletions, aiming to identify rare tumour suppressors. Our analysis defines 96 genomic regions recurrently targeted by homozygous deletions. These recurrent homozygous deletions occur either over tumour suppressors or over fragile sites, regions of increased genomic instability. We construct a statistical model that separates fragile sites from regions showing signatures of positive selection for homozygous deletions and identify candidate tumour suppressors within those regions. We find 16 established tumour suppressors and propose 27 candidate tumour suppressors. Several of these genes (including MGMT, RAD17, and USP44) show prior evidence of a tumour suppressive function. Other candidate tumour suppressors, such as MAFTRR, KIAA1551, and IGF2BP2,?are novel. Our study demonstrates how rare tumour suppressors can be identified through copy number meta-analysis.
机译:纯合子缺失在癌症中很少见,通常靶向肿瘤抑制基因。在这里,我们建立了涵盖12种人类癌症的2218种原发性肿瘤的纲要,并系统性地筛选了纯合缺失,旨在鉴定罕见的肿瘤抑制因子。我们的分析定义了纯合缺失反复靶向的96个基因组区域。这些反复的纯合缺失发生在抑癌基因或脆弱部位,即基因组不稳定性增加的区域。我们构建了一个统计模型,该模型从显示为纯合缺失阳性选择的特征的区域中分离出脆弱的位点,并在这些区域内识别候选肿瘤抑制因子。我们发现了16种已建立的肿瘤抑制因子,并提出了27种候选肿瘤抑制因子。这些基因中的几个(包括MGMT,RAD17和USP44)显示出肿瘤抑制功能的先验证据。其他候选的肿瘤抑制因子,例如MAFTRR,KIAA1551和IGF2BP2,是新颖的。我们的研究表明如何通过拷贝数荟萃分析鉴定出罕见的肿瘤抑制因子。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号